OncoSolid™ Breast Cancer Organoid Model based CAR-T In Vitro Efficacy Assay Service

Online Inquiry

All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.

Brief Description

Organoids are feasible tridimensional models that maintain the complexity of primary and metastatic human tumors. Patient tumor tissue-derived organoids mirror the biological and physiological characteristics of parental tumors and are cost-effective in vitro models to profile sensitivity and resistance to therapies of human tumors.

Breast cancer ranks first in occurrence rate and mortality among cancers in women populations worldwide. Creative Biolabs offers a large bank of breast cancer organoid models across various breast cancer subtypes to help determine promising CAR-T therapeutic responses in vivo.

Fig.1 Establishing breast cancer organoids as in vitro models. (Ebrahimi, et al., 2022)

Breast Cancer Organoid Characterization

Histological Characterization

Techniques

Functions

Hematoxylin and eosin staining

Histological phenotype

Immunohistochemistry

Cellular phenotype

RT-PCR

Cell identification

Live image analysis

Hormone receptor analyses

Organoid growth

Genetics Characterization

DNA sequencing

Comman somatic mutations

RNA sequencing

Unique cancer-associated mutation

Copy number(CN)changes

Epigenetic analysis

The established organoid models of breast cancer are evaluated on histological and molecular levels to analyze whether they are consistent with the parent tumor.

Features of Our Breast Cancer Organoid Biobank

Breast Cancer-related Targeted CAR-T Products at Creative Biolabs

Target Antigen	Target Description	CAR-T Products
CEA	The expression level of Carcinoembryonic antigen (CEA) is low in blood, but elevated in several cancer tissues, such as breast, colon, and pancreas, and is an indicator of poor prognosis for breast cancer.	Anti-CEA CAR-T
CD70	CD70 is a member of TNF superfamily and is highly expressed on the surface of breast cancer, renal cell carcinoma, and some lymphomas.	Anti-CD70 CAR-T
c-MET	Overexpression of c-MET is found in 20-30% of breast cancers and is related to poor outcomes.	Anti-c-Met CAR-T

CAR-T Therapy-related Products
CAR Vector Products CAR Cells CAR-viral Particle Products CAR Jurkat Cell Products CAR Lentivirus Packaging Kit Kits for CARs/TCRs Development

Case Study

Responses of Breast Cancer Organoids to CAR-T and TCR-T Therapies
Highlights: The behavior of immune cells and cancer organoids can be monitored by innovative BEHAV3D- a multispectral imaging system. Specific CAR-T cells are super engaged in antigen-expression PDOs of breast cancer.
Fig.2 ROR1 CAR-T and WT1 TCR-T showed significant cytotoxicity against breast cancer organoids. (Dekkers, et al., 2023)
Fig.3 The action of engineered T cells against organoids is classified into 9 groups, from dying to engagement. (Dekkers, et al., 2023)

Organoids developed in Creative Biolabs reliably recapitulate original tumor tissue cytology and histology and express verified antigens for your CAR-T development studies. If you want more information about our service, please contact us without hesitation.

References

Ebrahimi, Nasim.; et al. The potential application of organoids in breast cancer research and treatment. Human Genetics. 2022, 141.
Dekkers, J. F.; et al. Uncovering the mode of action of engineered T cells in patient cancer organoids. Nature biotechnology. 2023, 41(1): 60–69.